BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

globenewswire.com - 2026-07-14 10:31:00

Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.

fool.com - 2026-07-14 08:00:00

Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.

fool.com - 2026-07-13 14:27:07

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.

marketbeat.com - 2026-07-11 17:03:07

It is getting acquired by a larger firm in the sector.

fool.com - 2026-07-10 15:02:32

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

247wallst.com - 2026-07-09 13:29:39

NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) related to its sale to Vertex Pharmaceuticals Incorporated.

prnewswire.com - 2026-07-09 13:22:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.

businesswire.com - 2026-07-08 12:33:00

Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.

marketbeat.com - 2026-07-08 09:05:32

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-07-08 03:55:16

Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.

fool.com - 2026-07-08 03:28:53

Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in combined peak-sales potential.

fool.com - 2026-07-07 23:00:00

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transaction may contain terms that could limit superior competing offers.

globenewswire.com - 2026-07-07 11:45:00

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

zacks.com - 2026-07-07 10:31:29

Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.

invezz.com - 2026-07-07 09:38:25

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. ("Crinetics Pharmaceuticals" or the "Company") (NASDAQ: CRNX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The investigation concerns whether the Crinetics Pharmaceuticals Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

newsfilecorp.com - 2026-07-07 09:28:00

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash).

benzinga.com - 2026-07-07 08:24:14

Vertex snaps up Crinetics, Synopsys pivots to higher-margin AI offerings, and more

fool.com - 2026-07-07 07:30:00

AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.

barrons.com - 2026-07-07 06:35:00

Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) rose sharply in pre-market trading after the company announced it will be acquired by Vertex Pharmaceuticals (NASDAQ:VRTX).

benzinga.com - 2026-07-07 04:49:34

MILWAUKEE, July 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Click here  to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-07-06 19:41:00

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash. Halper Sadeh encourages Crinetics shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Crinetics a.

businesswire.com - 2026-07-06 17:53:00

The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.

wsj.com - 2026-07-06 17:02:00

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex Pharmaceuticals Inc (NASDAQ:VRTX).

benzinga.com - 2026-07-06 16:30:55

Vertex ​Pharmaceuticals ‌will buy ​Crinetics ​Pharmaceuticals ⁠for ​a total ​equity value ​of ​about $10 billion, ‌the ⁠companies said ​on ​Monday.

reuters.com - 2026-07-06 16:10:59

BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately.

businesswire.com - 2026-07-06 16:04:00

SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

globenewswire.com - 2026-06-30 16:05:00

Crinetics Pharmaceuticals maintains a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for acromegaly. The company advances atumelnant, its oral ACTH receptor antagonist, with promising phase 2 data for CAH and ACTH-dependent Cushing's syndrome. Q1 2026 Palsonify revenues reached $10.3M, beating expectations, but the company's cash runway remains limited to at least 12 months.

seekingalpha.com - 2026-06-25 16:48:25

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.

247wallst.com - 2026-06-25 08:15:12

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.

globenewswire.com - 2026-06-14 14:45:00

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

globenewswire.com - 2026-06-14 14:45:00

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions

globenewswire.com - 2026-06-02 16:05:00

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals

globenewswire.com - 2026-06-02 04:55:00

Oral presentation features open label extension PALSONIFY (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U. S. and E. U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing's syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.

globenewswire.com - 2026-06-02 04:55:00

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.

globenewswire.com - 2026-05-22 16:05:00

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

fool.com - 2026-05-18 13:50:27

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 02:11:20

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to a loss of $1.04 per share a year ago.

zacks.com - 2026-05-07 18:55:19

PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter       Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026.

globenewswire.com - 2026-05-07 16:05:00

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:06:24

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission's decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” said Scott Struthers, Ph.D.

globenewswire.com - 2026-04-27 17:13:00